Spruce Biosciences Closes on $88 Million Series B Round, Advancing CAH Program

BioSpace | February 20, 2020

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont for congenital adrenal hyperplasia (CAH). CAH is a rare genetic disorder that affects the ability of the adrenal glands to work appropriately. It is caused by a mutation in the gene that encodes for the enzyme 12-hydroxylase. As a result, people with CAH do not produce the hormone cortisol effectively, which can result in life-threatening adrenal crises.

Spotlight

Despite being a relatively new technique, NTA has been recognized as showing promise as an analytical method which could furnish not just information about nanoparticle size and, equally importantly, concentration but that it could do so in complex sample types of high polydispersity (Montes-Burgos et al., 2010; Lynch 2008, Montes-Burgos et al., 2007; Gornati et al., 2009) and that methods such as NTA could be considered as one of a number of means by which the environmental impact and potential cellular toxicity of nanoparticles could be studied in the future

Spotlight

Despite being a relatively new technique, NTA has been recognized as showing promise as an analytical method which could furnish not just information about nanoparticle size and, equally importantly, concentration but that it could do so in complex sample types of high polydispersity (Montes-Burgos et al., 2010; Lynch 2008, Montes-Burgos et al., 2007; Gornati et al., 2009) and that methods such as NTA could be considered as one of a number of means by which the environmental impact and potential cellular toxicity of nanoparticles could be studied in the future

Related News

PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

PharmaCyte Biotech | September 02, 2020

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Submitting this IND is the most important milestone the Company has met thus far in the clinical development of our leading product candidate. That’s our therapy to combat what is truly a global unmet medical need for those patients with LAPC whose tumors no longer respond to the first line treatments of either Abraxane® plus gemcitabine or FOLFIRINOX. “Now that the IND has been submitted, we must wait a minimum of 30 calendar days before initiating our clinical trial. During this time, the FDA has an opportunity to review the IND to ensure that it’s complete and that the planned clinical trial research patients will not be subject to unreasonable risk. It also gives the FDA time to ask for more information and clarification about the information submitted.

Read More

INDUSTRY OUTLOOK

BIOMEDICAN Enters the Astaxanthin Market Through Biosynthesis Platform to Target High-Value Compound and Disrupt the Current Technologies

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Astaxanthin market comprises of three primary segments: fish feed, animal feed, and human utilization. Astaxanthin's worth is developing astronomically: its market was worth over $1 billion in 2019 and is projected to be worth $3.3 billion by 2027.

Read More

ConcertAI Creates COVID-19 Resources for Oncology to Support Healthcare Providers, Biopharmaceutical Innovators, and Biomedical Researchers

ConcertAI | October 08, 2020

ConcertAI has launched a set of COVID-19 resources for oncology to support the needs of healthcare providers, biopharmaceutical innovators, and biomedical researchers as they look to maintain patient access to new and critical treatments and improve outcomes during this pandemic. Abstracted sets of aggregated, de-identified real-world data (RWD) will be derived from CancerLinQ Discovery™– a project of CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO). The initiative will provide actionable RWD and aligned AI technologies to improve healthcare operations and augment COVID-19 decision-making for oncology care providers. The solutions will also support the ability of critical oncology biopharma innovators to more rapidly redesign stalled clinical research programs and reconsider approaches to new clinical studies based on changes to standard of care, greater use of telehealth tools, and the vulnerabilities of specific groups of cancer patients. Specifically, healthcare providers will gain high-value insights to guide their responses to COVID-19 within their practice settings and biopharma innovators will be able to reinitiate studies and inform the redesign of new studies. ConcertAI will combine CancerLinQ Discovery clinical data with administrative payer claims data to create a complete longitudinal view of a focused population of cancer patients under active treatment.

Read More